Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T19:46:37.245Z.
Calculation as of: 2026-10-06T19:46:37.245Z.
Quote observation: 2026-10-06T19:45:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: de430a97f2ce1d56e5593aeaf7513a4829955f1ae9df1fe435740c279e59bff8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.34B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.35B
Operating Cash Flow Yield
N/A
TTM Avg
45.43%
3Y Avg
45.23%
5Y Avg
45.23%
Market Cap
$1.31B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.36B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
Operating Cash Flow Yield
3.84%
TTM Avg
4.59%
3Y Avg
4.10%
5Y Avg
4.07%
Market Cap
$1.39B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.41B
Operating Cash Flow Yield
1.28%
TTM Avg
0.67%
3Y Avg
0.67%
5Y Avg
1.44%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.34B | N/A | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.35B | N/A | 45.43% | 45.23% | 45.23% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.36B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 3.84% | 4.59% | 4.10% | 4.07% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.39B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.39B | N/A | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 1.28% | 0.67% | 0.67% | 1.44% |
| Omada Health (OMDA)vs › | $1.23B | 1.92% | 2.00% | 2.00% | 2.00% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
